Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-08-14 17:12:22 ET · period of report 2026-08-12 · accession 0001539937-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-14 17:12 | 2026-08-12 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | +29.8K | 1.27M | +2% | $0 |
| D | 2026-08-14 17:12 | 2026-08-12 | SUPN | Khattar Jack A. | Pres, CEO, Dir | F - Tax | $46.57 | -12.6K | 1.26M | -1.0% | -$588.7K |
| D | 2026-08-14 17:12 | 2026-08-12 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | -29.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-12 | M | A | 29,849 | $0.00 | 1,270,993 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-12 | F | D | 12,642 | $46.57 | 1,258,351 | D | — | — | (F1) Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| 3 | Derivative | Performance Share Unit | 2026-08-12 | M | D | 29,849 | $0.00 | 0 | D | $0.00 · — to — | 29,849 Common Stock | (F2) On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. (F2) On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |